Head of Corporate Development & Portfolio Manager, Ascend Gene and Cell Therapies
Freddie is part of the investment team at Monograph Capital and currently deployed in Ascend Gene and Cell Therapies, a Monograph Capital portfolio company, as Head of Corporate Development & Portfolio Manager. Ascend is a new gene and cell therapy manufacturing company pursuing a hybrid model of innovator, program accelerator and manufacturer. Previously, Freddie was a Partner at Syncona, a London based life science focussed venture firm, where he was involved in a number of investments, most notably, Clade Therapeutics, Forcefield Therapeutics and Quell Therapeutics, where he held Board Observer roles. Prior to Syncona, he was a member of the Investment Team at the Wellcome Trust. Freddie holds a degree in Biochemistry from the University of Edinburgh.
Stevenage Bioscience Catalyst30 November 2023